The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Rational design of cationic lipids for siRNA delivery
Abstract
We adopted a rational approach to design cationic lipids for use in formulations to deliver small interfering RNA (siRNA). Starting with the ionizable cationic lipid 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), a key lipid component of stable nucleic acid lipid particles (SNALP) as a benchmark, we used the proposed in vivo mechanism of action of ionizable cationic lipids to guide the design of DLinDMA-based lipids with superior delivery capacity. The best-performing lipid recovered after screening (DLin-KC2-DMA) was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/kg in nonhuman primates. To our knowledge, this represents a substantial improvement over previous reports of in vivo endogenous hepatic gene silencing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are limited published data on the in vivo delivery of self-amplifying RNA using nonviral delivery strategies (3,14,18), and none has taken advantage of the recently developed, clinically suitable delivery systems for siRNA (19,20).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [19]
In the citing paper
“Recently, there has been an exponential growth in the development of clinically suitable nonviral delivery systems for siRNA (19,20); we have taken advantage of these innovations to develop the LNP/RNA formulation and have now embarked on a more extensive evaluation of other nonviral delivery systems.”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [19]
In the citing paper
“They can also increase the transport efficiency of siRNA by lowering toxicity and enhancing biological dispersion.319”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [319]
In the citing paper
“considerable effort has been made to reduce the siRNA payload by developing different lipid formulations for delivery, which has so far led to a tenfold or even 100-fold reduction in the dose of siRNA administered to different models77,78.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [77]
In the citing paper
“Semple et al. reported that DLin-KC2-DMA containing stable nucleic acid lipid particles (SNALPs) exhibited in vivo activity at siRNA doses of 0.01 mg/kg in the mouse model and was capable of silencing the TTR gene in nonhuman primates with ED50 around 0.3 mg/kg.[63]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [63]
Citations
Cites
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Self-citationPotent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Self-citationA combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Self-citationMechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection,
Xu, Y., & Szoka, F. C. (1996) · Biochemistry · doi:10.1021/bi9602019 · Cited by 1,136
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 645
Self-citationMechanism of oligonucleotide release from cationic liposomes.
Zelphati, O., & Szoka, F. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11493 · Cited by 634
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Self-citationCationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,003
Matsui, H., Sato, Y., Hatakeyama, H., Akita, H., & Harashima, H. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.044 · Cited by 29
Apolipoprotein B Knockdown by AAV-delivered shRNA Lowers Plasma Cholesterol in Mice
Koornneef, A., Maczuga, P., van Logtenstein, R., Borel, F., Blits, B., Ritsema, T., van Deventer, S. J. H., Petry, H., & Konstantinova, P. S. (2011) · Molecular Therapy · doi:10.1038/mt.2011.6 · Cited by 32
“Chemical modifications and conjugations resulting in lower effective dose and longer half-life of the siRNA have improved their efficacy [12,13].”
BackgroundChemically defined polyethylene glycol siRNA conjugates with enhanced gene silencing effect
Gaziova, Z., Baumann, V., Winkler, A.-M., & Winkler, J. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.004 · Cited by 29
Drug delivery system of therapeutic oligonucleotides
Asami, Y., Yoshioka, K., Nishina, K., Nagata, T., & Yokota, T. (2016) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2016.01065 · Cited by 30
“This is called a stable-nucleic-acid lipid particle (SNALP), widely used for delivery of siRNA (13,14).”
BackgroundNguyen, M. K., McMillan, A., Huynh, C. T., Schapira, D. S., & Alsberg, E. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01739h · Cited by 29
Zhao, Y., Wang, Z. M., Song, D., Chen, M., & Xu, Q. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102499 · Cited by 30
The Interplay of Endosomal Escape and RNA Release from Polymeric Nanoparticles
Cheung, T. H., & Shoichet, M. S. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c05176 · Cited by 33
Engineering the biophysical properties of lipid nanostructures for drug delivery
Menge, J., Yang, C., Weitz, D. A., & Jahnke, K. (2026) · Communications Materials · doi:10.1038/s43246-026-01073-5 · Cited by 30
“These lipids are typically neutral at physiological pH but become positively charged in the acidic environment of endosomes, enhancing their interaction with the endosomal membrane 233 .”
Nanomedicines Based on Recombinant Fusion Proteins for Targeting Therapeutic siRNA Oligonucleotides
Winkler, J. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.56 · Cited by 28
Trends in polymeric delivery of nucleic acids to tumors
Yousefi, A., Storm, G., Schiffelers, R. M., & Mastrobattista, E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.040 · Cited by 30
Dosta, P., Demos, C., Ramos, V., Kang, D. W., Kumar, S., Jo, H., & Borrós, S. (2021) · Cardiovascular Engineering and Technology · doi:10.1007/s13239-021-00518-x · Cited by 27
Erythrocyte membrane camouflaged siRNA/chemodrug nanoassemblies for cancer combination therapy
Xu, J., Chen, T., Sun, T., Yu, C., Yan, D., & Zhu, L. (2022) · Biomaterials Science · doi:10.1039/d2bm01478e · Cited by 28
Therapeutic Oligonucleotides with Polyethylene Glycol Modifications
Winkler, J. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.94 · Cited by 27
New Amphiphilic Carriers Forming pH-Sensitive Nanoparticles for Nucleic Acid Delivery
Xu, R., Wang, X.-L., & Lu, Z. (2010) · Langmuir · doi:10.1021/la1024185 · Cited by 28
Hennessy, E., & Moore, K. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829d48bf · Cited by 32
MicroRNAs as Multifaceted Players in Glioblastoma Multiforme
Mercatelli, N., Galardi, S., & Ciafrè, S. A. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.03.002 · Cited by 27
Nano-carriers for drug routeing – towards a new era
Reddy, L. H., & Bazile, D. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1561891 · Cited by 28
Berardo, C., Siciliano, V., Pasqua, L. G. D., Richelmi, P., Vairetti, M., & Ferrigno, A. (2019) · European Journal of Histochemistry · doi:10.4081/ejh.2019.3048 · Cited by 28
Microfluidics for Formulation and Scale-Up Production of Nanoparticles for Biopharma Industry
Yu, M., Mathew, A., Liu, D., Chen, Y., Wu, J., Zhang, Y., & Zhang, N. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-60717-2_16 · Cited by 27
Endogenous HClO-Gated Cascade MicroRNA Imaging for Precise Diagnosis of Atherosclerosis In Vivo
Ji, M., Dong, J., Ye, Z., Kang, J., Han, G., Hong, X., Wei, Y., Chen, X., Sun, W. Y., & Liu, D. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c00031 · Cited by 27
Martini 3 Building Blocks for Lipid Nanoparticle Design
Kjølbye, L. R., Valério, M., Paloncýová, M., Borges-Araújo, L., Pestana-Nobles, R., Grünewald, F., Bruininks, B. M. H., Araya‐Osorio, R., Šrejber, M., Mera‐Adasme, R., et al. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5c01207 · Cited by 28
Design principles of lipid nanoparticles for RNA delivery
Arral, M. L., & Whitehead, K. A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00401-1 · Cited by 41
Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology
Gomes-da-Silva, L. C., Simões, S., & Moreira, J. N. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1502-2 · Cited by 27
Liu, H., Qiao, C.-M., Yang, J., Weng, J., & Zhang, X. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb00814f · Cited by 27
Garber, K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3810 · Cited by 27
Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes
Yuan, Z., Zhao, L., Zhang, Y., Li, S., Pan, B., Hua, L., Wang, Z., Ye, C., Lu, J. L., Yu, R., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2966-6 · Cited by 28
Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing
Xu, Y., Liu, R., & Dai, Z. (2020) · Nanoscale · doi:10.1039/d0nr05452f · Cited by 27
Sato, Y. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00705 · Cited by 29
Recent advances in versatile inverse lyotropic liquid crystals
Shan, X., Luo, L., Yu, Z., & You, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.036 · Cited by 28
Ganbold, T., Bao, Q., Xiao, H. T., Zurgaanjin, D., Liu, C., Han, S., Hasi, A., & Baigude, H. (2022) · Nanomaterials · doi:10.3390/nano12122072 · Cited by 29
“However, major challenges, including development of efficient delivery systems still remain in realizing the full potential of RNAi-mediated therapeutics in clinic [16].”
BackgroundLipid nanoparticles to silence androgen receptor variants for prostate cancer therapy
Quick, J., Santos, N. D., Cheng, M. H. Y., Chander, N., Brimacombe, C. A., Kulkarni, J. A., van der Meel, R., Tam, Y. Y. C., Witzigmann, D., & Cullis, P. R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.051 · Cited by 30
Self-citationHe, T., Hu, M., Zhu, S., Shen, M., Kou, X., Liang, X., Li, L., Li, X., Zhang, M., Wu, Q., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.017 · Cited by 27
Ionizable drug delivery systems for efficient and selective gene therapy
Zhang, Y., Guo, R., Chen, Y., Li, T., Du, W.-Z., Xiang, R., Guan, J., Li, Y., Huang, Y., Yu, Z., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00445-z · Cited by 27
“A small amount of phosphatidylcholine is used to support stable ILNPs during the formation and recycling of ILNPs [87].”
BackgroundGenetically engineered transfusable platelets using mRNA lipid nanoparticles
Leung, J., Strong, C., Badior, K. E., Robertson, M. K., Wu, X., Meledeo, M. A., Kang, E., Paul, M., Sato, Y., Harashima, H., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi0508 · Cited by 32
Self-citationMontenegro, J., Fin, A., & Matile, S. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00948b · Cited by 27
Catalytic self-assembly of a DNA dendritic complex for efficient gene silencing
Lv, Y., Peng, R., Zhou, Y., Zhang, X., & Tan, W. (2015) · Chemical Communications · doi:10.1039/c5cc06937h · Cited by 27
Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis
Khaja, F., Jayawardena, D., Kuzmis, A., & Önyüksel, H. (2016) · Nanomaterials · doi:10.3390/nano6010008 · Cited by 27
“Therefore, chemical modification of the head groups of these molecules with cationic arginine molecules should promote entrapment of negatively charged siRNA through electrostatic interactions, making them promising components of siRNA nanocarriers [22,23].”
BackgroundMokhtarieh, A. A., Lee, J., Kim, S., & Lee, M. K. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.027 · Cited by 27
Basha, G., Cottle, A. G., Pretheeban, T., Chan, K. Y. T., Witzigmann, D., Young, R. N., Rossi, F. M. V., & Cullis, P. R. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.012 · Cited by 26
Self-citationZhong, Q., Zheng, C., Yi, K., Mintz, R. L., Lv, S., Tao, Y., & Li, M. (2023) · Biomaterials Science · doi:10.1039/d3bm00387f · Cited by 26
Mechanisms and Delivery of tRNA Therapeutics
Ward, C., Beharry, A., Tennakoon, R., Rozik, P., Wilhelm, S. D. P., Heinemann, I. U., & O’Donoghue, P. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00142 · Cited by 25
“…be such that they contain a positive charge during assembly to package negatively charged DNA, but have a neutral charge at physiological pH. 372 373 − 375 It is especially relevant to design LNPs that can fuse with and lyse endosomes aslysosomal clearance of LNPs is a significant challenge to…”
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27
Short Interfering RNA (siRNA)-Based Therapeutics for Cartilage Diseases
Zhou, L., Rubin, L. E., Liu, C.-J., & Chen, Y. (2020) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-020-00149-z · Cited by 25
Nanomaterials for gene delivery and editing in plants: Challenges and future perspective
Gad, M. A., Li, M., Ahmed, F. K., & Almoammar, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821354-4.00006-6 · Cited by 26
Sousa, D. A., Gaspar, R., Ferreira, C. J. O., Baltazar, F., Rodrigues, L. R., & Silva, B. F. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051087 · Cited by 26
“A related type of lipid nanodelivery system, using ionizable lipids that are cationic only at lower pH [22,43,44], is the base of current mRNA vaccines being used worldwide for COVID-19 prevention [45,46].”
BackgroundHou, Y., Zhang, C., Zhang, Z., Xia, L., Rao, K., Gu, L., Wu, Y., Lv, Z., Wu, H., Zuo, X., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200579 · Cited by 26
Application of mRNA Technology in Cancer Therapeutics
Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27
Chen, W., Chen, Y., Ren, Y., Gao, C., Ning, C., Deng, H., Li, P., Ma, Y., Li, H., Fu, L., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121888 · Cited by 27
Stabilization of polyplexes via polymer crosslinking for efficient siRNA delivery
Fröhlich, T., Edinger, D., Ruß, V., & Wagner, E. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.09.006 · Cited by 26
Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01
Ashizawa, A. T., & Cortes, J. E. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.996545 · Cited by 26
“A screening process, starting with the cationic lipid DLin-DMA as a benchmark, identified 1,2-dilinoleyl4-(2-dimethylaminoethyl)- [1,3]-dioxolane (DLin-KC2-DMA) as the better-performing ionizable lipid [29].”
BackgroundMethodSynthesis and Characterization of Aptamer-Targeted SNALPs for the Delivery of siRNA
Wilner, S. E., & Levy, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3197-2_18 · Cited by 28
Lipidoid Tail Structure Strongly Influences siRNA Delivery Activity
Knapp, C. M., Guo, P., & Whitehead, K. A. (2016) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-016-0436-9 · Cited by 26
Wang, H., Chang, H. Y., Zhang, Q., & Cheng, Y. (2017) · Topics in Current Chemistry · doi:10.1007/s41061-017-0151-6 · Cited by 26
Perspectives, Issues and Solutions in RNAi Therapy: the Expected and the Less Expected
Aigner, A. M. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0321 · Cited by 25
Sato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.006 · Cited by 25
Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics
Yuan, Y., Li, Y., Li, G., Lei, L., Huang, X., Li, M., & Yao, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00925 · Cited by 28
Hurdles to healing: Overcoming cellular barriers for viral and nonviral gene therapy
Honrath, S., Burger, M., & Leroux, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125470 · Cited by 28
Ge, X., He, Z., Yang, H., Pan, X., Yan, L., Shi, Y., Chen, Y., & Liu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113906 · Cited by 25
Amoako, K. A., Mokhammad, A., Malik, A., Yesudasan, S., Wheba, A., Olagunju, O., Gu, S. X., Yarovinsky, T. O., Faustino, E. V. S., Nguyen, J., et al. (2025) · Frontiers in Medical Technology · doi:10.3389/fmedt.2025.1591119 · Cited by 31
Application of DODMA and Derivatives in Cationic Nanocarriers for Gene Delivery
Zhou, C., Zhang, A., Yang, Z., Wang, X., Chang, L., Chen, Z., & Lee, L. J. (2016) · Current Organic Chemistry · doi:10.2174/1385272820666160202004348 · Cited by 25
Optimized Solid‐Phase‐Assisted Synthesis of Oleic Acid Containing siRNA Nanocarriers
Reinhard, S., Zhang, W., & Wagner, E. (2017) · ChemMedChem · doi:10.1002/cmdc.201700350 · Cited by 25
RNAi therapeutic strategies for acute respiratory distress syndrome
Jagrosse, M. L., Dean, D. A., Rahman, A., & Nilsson, B. L. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.011 · Cited by 25
Kunz, M., Brandl, M., Bhattacharya, A., Nobereit-Siegel, L., Ewe, A., Weirauch, U., Hering, D., Reinert, A., Kalwa, H., Guzman, J., et al. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00728-w · Cited by 25
Pei, Y., Bao, Y., Sacchetti, C., Brady, J., Gillard, K., Yu, H., Roberts, S., Rajappan, K., Tanis, S. P., Pérez‐García, C. G., et al. (2022) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2022.105178 · Cited by 26
CRISPR/Cas9 in the era of nanomedicine and synthetic biology
Schmidt, T. J. N., Berarducci, B., Konstantinidou, S., & Raffa, V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103375 · Cited by 26
Guanidinium-Rich Lipopeptide-Based Nanoparticle Enables Efficient Gene Editing in Skeletal Muscles
Zhu, M., Wang, X., Xie, R., Wang, Y., Xu, X., Burger, J. C., & Gong, S. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c21683 · Cited by 25
Effective Nanoparticle‐based Gene Delivery by a Protease Triggered Charge Switch
Gjetting, T., Jølck, R. I., & Andresen, T. L. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300503 · Cited by 25
Kulkarni, A., VerHeul, R., DeFrees, K., Collins, C. J., Schuldt, R. A., Vlahu, A., & Thompson, D. H. (2013) · Biomaterials Science · doi:10.1039/c3bm00189j · Cited by 25
Formulation of RNA interference-based Drugs for Pulmonary delivery: Challenges and Opportunities
Thanki, K., Blum, K. G., Thakur, A., Rose, F., & Foged, C. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0029 · Cited by 25
Luvino, D., Khiati, S., Oumzil, K., Rocchi, P., Camplo, M., & Barthélémy, P. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.006 · Cited by 25
Hattori, Y., Nakamura, T., Ohno, H., Fujii, N., & Maitani, Y. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.12.017 · Cited by 25
Gonçalves, N. P., Teixeira-Coelho, M., & Saraiva, M. J. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.030 · Cited by 27
Targeted Delivery of RNAi Therapeutics for Cancer Therapy
Li, J., & Huang, L. (2010) · Nanomedicine · doi:10.2217/nnm.10.124 · Cited by 24
In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
Esteban, I., Pastor-Quiñones, C., Usero, L., Plana, M., García, F., & Leal, L. (2021) · Viruses · doi:10.3390/v13030501 · Cited by 26
“While liposomes represent a promising vehicle to deliver exogenous mRNA into the cytosol of APCs, they still have some drawbacks that limit their efficacy, low stability, low efficiency of transfection, and high toxicity [59].”
BackgroundHausig, F., Sobotta, F. H., Richter, F., Harz, D. O., Traeger, A., & Brendel, J. C. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00829 · Cited by 24
Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles
Nakamura, T., Nakade, T., Sato, Y., & Harashima, H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122810 · Cited by 24
Song, H., Huang, W., Jia, F., Wang, Z., Zhang, J., Qian, R., Nie, G., & Wang, H. (2023) · ACS Nano · doi:10.1021/acsnano.3c09536 · Cited by 24
Cell-Specific siRNA Delivery by Peptides and Antibodies
Lee, S., Siefert, A. L., Beloor, J., Fahmy, T. M., & Kumar, P. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416039-2.00005-7 · Cited by 24
“primates, factor VII siRNA Semple et al. (2010)”
Polycation liposomes as a vector for potential intracellular delivery of microRNA
Ando, H., Okamoto, A., Yokota, M., Asai, T., Dewa, T., & Oku, N. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2744 · Cited by 24
“[14] developed lipid nanoparticles composed of an ionizable cationic lipid (DLin-KC2-DMA) for in vivo delivery of siRNA, Kim et al.”
BackgroundShi, B., & Abrams, M. T. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413484152 · Cited by 24
Designing idiosyncratic hmPCL -siRNA nanoformulated capsules for silencing and cancer therapy
Kumar, V. B., Medhi, H., Zhang, Y., & Paik, P. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.10.007 · Cited by 24
Solmesky, L. J., Shuman, M., Goldsmith, M., Weil, M., & Peer, D. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/49/494016 · Cited by 24
“global cell counts of leukocyte subsets when injecting novel formulations into animal models [6, 7].”
BackgroundPEGylation of 6-amino-6-deoxy-curdlan for efficient in vivo siRNA delivery
Altangerel, A., Cai, J., Liu, L., Wu, Y., Baigude, H., & Han, J. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.12.077 · Cited by 24
Biomaterials for polynucleotide delivery to anchorage-independent cells
Ansari, A. S., Santerre, P., & Uludağ, H. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01833a · Cited by 23
Martins, D. F., Moreira, J., Gonçalves, N. P., & Saraiva, M. J. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.028571 · Cited by 24
“For TTR siRNA treatment, Hsf/V30M mice (5 months) were injected in the tail vein with a human TTR siRNA (Semple et al., 2010), at a concentration of 1 mg/kg over 4 weeks.”
Light-Triggered Cellular Delivery of Oligonucleotides
Kontturi, L.-S., van den Dikkenberg, J. B., Urtti, A. O., Hennink, W. E., & Mastrobattista, E. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020090 · Cited by 24
Zhou, C., Zhang, Y., Yu, B., Phelps, M. A., Lee, L. J., & Lee, R. J. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.10.002 · Cited by 24
Neumann, U. H., Chen, S., Tam, Y. Y. C., Baker, R. K., Covey, S. D., Cullis, P. R., & Kieffer, T. J. (2014) · Endocrinology · doi:10.1210/en.2013-1622 · Cited by 24
“We selected lipid nanoparticles as a vehicle for IGFBP2 siRNA delivery, because lipid nanoparticles efficiently target siRNA to the liver in vivo (24, 25), and the liver is suspected to be a major source of circulating Figure 2.”
MethodSelf-citationEffect of catecholamines on IL-2 production and NK cytotoxicity of rats in vitro.
Peng, Y.-P., Qiu, Y., Jiang, J., & Wang, J. (2004) · PubMed · Cited by 24
Distinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response
Dowell, W. R., Dearborn, J. S., Languon, S., Miller, Z. D., Kirch, T., Paige, S., Garvin, O., Kjendal, L., Harby, E., Zuchowski, A. B., et al. (2024) · The Journal of Immunology · doi:10.1021/acsnano.4c08490 · Cited by 23
Monitoring mRNA vaccine antigen expression in vivo using PET/CT
Blizard, G. S., Dwivedi, G., Pan, Y., Hou, C., Etersque, J. M., Said, H., Chevrier, A., Lavertu, M., Ni, H., Davis, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57446-w · Cited by 25
“Given the broad scope of diseases with potential to be treated by mRNA vaccines, ef fi cient in vivo delivery and cellular expression in target tissues is crucial and achieved through formulation of mRNA into carrier molecules such as lipid nanoparticles (LNPs) 3 .”
Self-citationOliveira, C. L., Silveira, I., Veiga, F., & Ribeiro, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.945421 · Cited by 23
“For instances, the number of cis-double bonds or introduction of different chemical groups within the lipid structure greatly impact on size, acid-dissociation constant and ionizable groups conducing to different vector performances [43,44].”
BackgroundHow to Tackle the Challenge of siRNA Delivery with Sequence‐Defined Oligoamino Amides
Reinhard, S., & Wagner, E. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600152 · Cited by 23
Akita, H. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00534 · Cited by 23
Deng, J., Fukushima, Y., Nozaki, K., Nakanishi, H., Yada, E., Terai, Y., Fueki, K., & Itaka, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091785 · Cited by 27
De, A., & Ko, Y. T. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2153832 · Cited by 24
“To avoid endosomal nucleic acid release, ionizable LNPs remain in the lamellar phase during circulation and transit to the inverse hexagonal phase at endosomal acidic pH [54].”
BackgroundPhosphatidylcholine Liposomes Reprogram Macrophages toward an Inflammatory Phenotype
Cauvi, D. M., Hawisher, D., Derunes, J., & Maio, A. D. (2023) · Membranes · doi:10.3390/membranes13020141 · Cited by 24
“Thus, the nucleic acids are loaded into liposomes at low pH, increasing the internal concentration of the substrate [2,8].”
Qin, Y., Walters, A. A., Rouatbi, N., Wang, J. T.-W., Abdel‐Bar, H. M., & Al‐Jamal, K. T. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122158 · Cited by 24
Inspired By Nature: Fundamentals in Nanotechnology Design to Overcome Biological Barriers
Avila-Olias, M., Pegoraro, C., Battaglia, G., & Cantón, I. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.126 · Cited by 23
Tadin‐Strapps, M., Robinson, M., LeVoci, L., Andrews, L. E., Yendluri, S., Williams, S., Bartz, S., & Johns, D. G. (2015) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-014-9605-1 · Cited by 23
“siRNAs offer high target specificity and selectivity and have been successfully used for gene knockdown across preclinical species [12, 16, 21–23].”
Metadata
- Authors
- Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., Hafez, I. M., Dorkin, J. R., Qin, J., Lam, K., Rajeev, K. G., Wong, K. F., Jeffs, L. B., Nechev, L., Eisenhardt, M. L., Jayaraman, M., Kazem, M., Maier, M. A., Srinivasulu, M., Weinstein, M. J., Chen, Q., Alvarez, R., Barros, S. A., De, S., Klimuk, S. K., Borland, T., Kosovrasti, V., Cantley, W. L., Tam, Y. K., Manoharan, M., Ciufolini, M. A., Tracy, M. A., de Fougerolles, A., MacLachlan, I., Cullis, P. R., Madden, T. D., & Hope, M. J.
- Affiliations
- Arbutus Biopharma (Canada) (CA)
- Alnylam Pharmaceuticals (United States) (US)
- University of British Columbia (CA)
- Corresponding author
- Semple, Sean C
- Akinc, Akin
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2010-01-17
- Volume
- 28
- Issue
- 2
- Pages
- 172-176
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2083249633
- Cited by
- 1,822
- References
- 24
- Citations by year
- 2026: 124 · 2025: 165 · 2024: 175 · 2023: 145 · 2022: 145 · 2021: 119 · 2020: 90 · 2019: 102 · 2018: 83 · 2017: 85 · 2016: 95 · 2015: 85 · 2014: 105 · 2013: 103 · 2012: 98
- FWCI
- 39.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alnylam Pharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- siRNA delivery, lipid nanoparticles, RNAi therapeutics, ionizable cationic lipids
- MeSH terms
- Cations, Drug Carriers, Drug Compounding, Lipids, Transfection, Drug Design, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
